Introduction
The pulmonary artery floronon catheter (PAF() has naw been in use for over .30 years; however, its benefit remains unproven. The Connors study ( ) in 1996 suggested an increased mortality from the use of a PAFC. The study generated much discussion from advocates both for and against, however the agreed outcome was that more research was needed. The Canadian Critical Care Trials Group have now published this prospective multicentre randomised trial involving almost 2000 patients from 19 centres over a 9 year period.
Patients recruired were over 60, ASA .3 ar 4 and were scheduled for major surgery. Portents in the rrearment group had the PAFC placed prior ro surgery and treatment was administered on a goal directed therapy basis as outlined in table 1. All patients received thromboprophylaxis with low dose subcutaneous heparin and had a minimum 24 hours of postoperative ICU care. The primary outcome was in hospital mortality.
Table 1. Gooll In order of priority
The patients appear to have been well randomised between the two groups (997 in each). Although the total number of patients recruited is impressive and approaches the authors aim of 1000 in each group (to achieve 90% power) with 52% recruitment rate this only amounts to an average of 12 patients being recruited by each unit per year. This small number may reflect changing practices or patient exclusions.
Crossover from standard care to use of a PAFC occurred in 24 patients. 77% of patients in the control group had a central venous catheter, placed at the discretion of the anaesthetist. There was no difference in the CVP between rhe groups. Despire having the PAFC placed prior to surgery for optimisation the majority of patients did not achieve the desired goals for cardiac index ar oxygen delivery until the postoperative period. The major treatment differences are outlined in table 2.
PrIorlty
Goal 
Mortality
Despite the significant differences in some of the treatments administered there was no difference in the overall mortality between the 2 groups. Inhospital mortality was 77 in cantrol group and 78 in the treated group. Survival figures at 6 months and 1 yeor were again similar with on adjusted risk ratio for death of 1.0 (95% confidence interval. 0.7 -1.3)
Morbidity
Pulmonary embolism was significantly (p=0.004) more cammon in the catheter group (8 patients vs. Q) The authors highlight this difference in their discussion, however the catheter group hod significantly (p=0.05) less patients receiving thromboprophylaxis than the cantrol arm and it seems unusual in a group of 1000 high-risl~patients to have hod no occurrences of thromboembolic events.
Other results show a trend towards less renal insufficiency in the catheter group (defined as a 50% increase in serum creatinine or need for dialysis) 7.4% of catheter group vs. 9.8% conrrols (p= 007)
Conclusion
This study shows that PAFCs do not have any effect on overall mortality in elderly high-risk patients; however there may be a small increase in the incidence of pulmonory embolism. The study cannot be viewed as a pre-optimisation study as most goals were nat achieved until the postoperative period. 
